HighLight Capital
VC Fund
Shanghai, China
HighLight Capital is a VC fund in Shanghai focused on Biotechnology and Medical. HLC targets companies in healthcare, life sciences, and wellness sectors, including medical devices, pharmaceuticals, biotech, diagnostics, digital health, and consumer health products. It follows a value-oriented, research-driven investment strategy, emphasizing deep industry analysis and long-term value creation rather than puregrowth-at-all-costs.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries HighLight Capital invests in
Stages HighLight Capital invests in
Countries HighLight Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Steven Wang
|
|||
Investment Focus
Industry
- Biotechnology 2 (50%)
- Medical 1 (25%)
- Chemical 1 (25%)
- Oncology 1 (25%)
- Health Care 1 (25%)
Stage
- Seed 1 (25%)
- Series A 1 (25%)
- Series B 1 (25%)
- Venture - Series Unknown 1 (25%)
Country
- Germany 1 (25%)
- Indonesia 1 (25%)
- Switzerland 1 (25%)
- United States 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Steven Wang
CEO & Founder
|
CEO & Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aureka Biotechnologies
|
Aureka Biotechnologies is a pioneering biotech firm dedicated to democratizing the pharmaceutical sector in order to conquer sickness. | $100M / Series B / Aug 10, 2026 | |
T-CURX
|
T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell therapies to address the challenges faced in treating various cancers. The company's innovative approach involves the creation of a new generation of T cells designedto improve patient outcomes. As a spin-out from the University Clinics Würzburg, Germany, T-CURX leverages the expertise of its co-founders, including Prof. Michael Hudecek, to pioneer in the area of CAR-T cell-based medicines. With a commitment to transforming cancer treatment, T-CURX is at the forefront of developing targeted therapies that offer hope for a more effective and personalized approach to cancer care. | $20M / Series A / Dec 17, 2025 | |
Allegria Therapeutics
|
Allegria Therapeutics operates as a biotech company. | $5.1M / Seed / Dec 11, 2025 | |
Tawada Healthcare
|
Tawada Healthcare was with the goal of becoming the most integrated, reliable, and customer-driven healthcare provider in Indonesia. Through the years, we have added various different brands and products to our portfolio in order to serve even more customer base. We are focused on providing the best customer experience and to offer products of thebest quality to our Indonesian customers. Today, Tawada Healthcare is one of the largest and most comprehensive healthcare, medical devices, and medical consumables provider in Indonesia. | Venture - Series Unknown / May 29, 2025 |
Co-Investors
ALK Abelló
1 deal together
Bayern Kapital
1 deal together
BioMedPartners
1 deal together
Forty51 Ventures
1 deal together
Granite Asia
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does HighLight Capital invest in?
HighLight Capital invests primarily in Biotechnology, Medical and Chemical startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact HighLight Capital?
Public channels for HighLight Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at HighLight Capital?
The team at HighLight Capital includes Steven Wang (CEO & Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
